In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cytokinetics Stays the Course

Executive Summary

Cytokinetics claims to have implemented a far more detailed long-term strategic plan than most biotechs. That plan will be put to the test as it enters the clinic with an acute CHF compound. Until now, the company has relied on a partner (GSK) to shoulder the burden of developing its drug candidates. Now it will have to do that heavy lifting, at least for a while, on its own.
Advertisement

Related Content

Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Theravance: Having Cake and Eating It
Exelixis/GSK: Using Project Financing to Accelerate R&D
Exelixis/GSK: Using Project Financing to Accelerate R&D
Feeding the Machine: Exelixis Buys X-Ceptor
Feeding the Machine: Exelixis Buys X-Ceptor

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel